Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabasis Therapeutics, a biopharmaceutical company, has announced that Paul Laikind has resigned as its president and CEO to pursue other opportunities. Dr Laikind will continue to serve as a member of the board of directors.
Subscribe to our email newsletter
In conjunction with Dr Laikind’s resignation, the company has appointed Mark Erion, chief scientific officer and executive vice president of R&D and a member of Metabasis board of directors, as its new president, CEO and chief scientific officer.
Dr Erion is one of the founders of Metabasis and has served as executive vice president of R&D since April 1997 and on the board of directors since June 1999. In November 2005, he was appointed chief scientific officer.
At Metabasis, Dr Erion has been responsible for building the R&D teams that advanced five candidates into clinical development and for discovering the company’s HepDirect and NuMimetic technologies. Prior to Metabasis, Dr Erion was at Gensia where he became vice president of research in 1996 after serving as its head of chemistry and biochemistry.
David Hale, chairman of the Metabasis board, said: “On behalf of the board of directors and the Metabasis team, I would like to thank Paul for his efforts over the past 10 years in leading Metabasis. Paul, Mark and the Metabasis team have built a promising pipeline of product candidates. We look forward to working with Mark to advance this product pipeline and to build long-term shareholder value.”